… cell lung cancer and the subsequent discovery of activating EGFR mutations have led to an
… of knowledge in the fields of EGFR biology, targeted therapeutics and lung cancer research. …

… EGFR TKIs. This review summarizes the current knowledge of EGFR TK domain mutations
and … the importance of EGFR mutation status in the selection of patients for EGFR TKI therapy. …

… lung cancer (median number, 74 cells per milliliter). We identified the expected EGFR activating
mutation … We detected the T790M mutation, which confers drug resistance, in circulating …

… lung cancers with somatic EGFR mutations and that prospective clinical trials of EGFR inhibition
in patients with EGFR mutations … Identification of EGFR mutations in other malignancies, …

… to gefitinib or erlotinib harbor EGFR mutations, not all cases with such mutations demonstrate
a potent drug response. To address the predictive value of EGFR mutations, we analyzed …

… to EGFR inhibitor therapies. Initial data have indicated an increased frequency of activating
EGFR mutations in … the question of mutation distribution across the population of lung cancer. …

… In addition, detecting T790M may be useful for predicting pretreatment resistance to EGFR
… role of EGFR mutations in the development of EGFR-related non–small-cell lung cancer and …

… B, Mechanisms of acquired resistance to EGFR TKIs in EGFR mutated non-small-cell lung
cancer (NSCLC) with emphasis on the EGFR-T790M resistant mutation and oncogene bypass …

… This study reviewed the prevalence of uncommon EGFR mutations and their sensitivity to
EGFR… L858R mutations, indicating that they may benefit from EGFR-TKIs as a first-line therapy. …

… , because EGFR mutations are … of lung cancer, survival of patients with EGFR mutations
tends to be longer in those who undergo surgery only. To determine whether EGFR mutations …